Tiziana Life Sciences Ltd (TLSA NASDAQ) stock market data APIs
$1.5028
0.07(4.7%)
as of July 3, 2025
Try our APIs with
free plan!
Tiziana Life Sciences Ltd Financial Data Overview
Price chart is built with
Anychart
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Prev. Close
1.5028
Open
1.5734
High
1.5734
Low
1.5028
52 wk Range
0.6295-1.91
Market Cap
176 M
Shares Outstanding
117 M
Revenue
-3 595 000
EPS
-0.07
Beta
0.107
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tiziana Life Sciences Ltd data using free add-ons & libraries
Get Tiziana Life Sciences Ltd Fundamental Data
Tiziana Life Sciences Ltd Fundamental data includes:
- Net Revenue: -3 595 000
- EBITDA: -15 782 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-23
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tiziana Life Sciences Ltd News
New
Tech Voices: OpenAI warns on stock tokens, CoreWeave-Nvidia, Apple
[Moscow, Russia - April 7, 2019: NVIDIA video chip on the motherboard] Antonio Bordunovi _Seeking Alpha's daily roundup of statements and remarks that could impact the technology sector._ * OpenAI ...
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapie...
Tiziana shares rise on presentation date for foralumab data
[Laptop computer stand on wooden meeting table] BongkarnThanyakij/iStock via Getty Images * Tiziana Life Sciences (NASDAQ:TLSA [https://seekingalpha.com/symbol/TLSA]) shares rose on Friday after th...
Tiziana Life Sciences to Present at the Bio International Convention
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapie...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
